Visit Contract Pharma
at Booth #1921

Ajinomoto Bio-Pharma Services, Precision Nanosystems in Mfg. Pact

10.23.18

Will leverage PNI's NanoAssemblr to support clients into clinical development through to commercialization of nanomedicines

Precision Nanosystems Inc. (PNI) has entered into a manufacturing collaboration agreement with Ajinomoto Bio-Pharma Services to support clients into clinical development through to the commercialization of nanomedicines using PNI's NanoAssemblr Scale-Up system.
 
Ajinomoto Bio-Pharma Services is a contract development and manufacturing organization that provides preclinical and GMP manufacturing services from drug substance to fill & finish for clinical and commercial drug product.
 
The GMP NanoAssemblr system is modular and customizable to suit specific clients' needs and allows for continuous flow manufacture of nanomedicines under cGMP. Under this manufacturing collaboration, Ajinomoto Bio-Pharma Services and PNI will work together to support clients by providing a complete range of clinical development services from preclinical formulation, analytical and process development to GMP manufacturing of nanomedicines on the NanoAssemblr platform.
 
"Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's GMP NanoAssemblr Scale-Up system and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines" said Kristin DeFife, Ph.D., vice president and head of U.S. Operations of Ajinomoto Bio-Pharma Services.

"As we continue to accelerate the creation of transformative medicines, we are pursuing strategic collaborations that enable researchers to move quickly in the drug development process. We are very pleased to announce our collaboration with Ajinomoto Bio-Pharma Services as it exemplifies our goal to provide the NanoAssemblr platform for the seamless scale up from discovery to GMP manufacturing of the next generation nanomedicines" said James Taylor, co-founder and chief executive officer for PNI.